Kolexia
Fenaux Pierre Médecine générale
Fenaux Pierre
Médecine générale
Hôpital Saint-Louis
Paris, France
984 Activités
214 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Syndromes myélodysplasiques Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Leucémie myélomonocytaire chronique Préleucémie Anémie Thrombopénie Leucémie aiguë promyélocytaire

Collaborateurs

Voir plus
Ades Lionel
Ades Lionel
Hôpital Saint-Louis, Paris, France
Itzykson Raphael
Itzykson Raphael
Hôpital Saint-Louis, Paris, France
Vey Norbert
Vey Norbert
Centre Paoli-Calmettes, Marseille, France
Rauzy Odile
Rauzy Odile
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France

Industries

Voir plus
Abbvie
42 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
11 collaboration(s)
Dernière en 2022
BMS
9 collaboration(s)
Dernière en 2023
Ipsen
6 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS): A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
Essai Clinique (BMS)   13 mars 2024
STIMULUS-MDS1: A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
Essai Clinique (Novartis)   12 mars 2024
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Essai Clinique (Syros Pharmaceuticals)   11 mars 2024
ELEMENT-MDS: A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD): The "ELEMENT-MDS" Trial
Essai Clinique (BMS)   11 mars 2024
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk: Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Low or Intermediate-1 Myelodysplastic Syndrome: A Prospective Multicenter Phase II Study Based on Donor Availability on Behalf of the GFM & SFGM-TC
Essai Clinique (Novartis)   29 février 2024
Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS): A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Essai Clinique (Geron Corporation)   28 février 2024
National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup
Essai Clinique (Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH)   22 février 2024
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML: Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy
Essai Clinique (Syros Pharmaceuticals)   21 février 2024
Germline CHEK2 mutations in patients with myeloid neoplasms.
Leukemia   20 février 2024
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation: A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination With Azacitidine or Cytarabine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation
Essai Clinique (Forma Therapeutics, Inc.)   18 février 2024